Funder
National Research Foundation of Korea
Publisher
Springer Science and Business Media LLC
Reference62 articles.
1. Howlader N, Noone A, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis D (2019) SEER cancer statistics review, 1975–2016, National Cancer Institute. Bethesda, MD 2020:1–10
2. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402–2416
3. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130
4. Childers CP, Childers KK, Maggard-Gibbons M, Macinko J (2017) National estimates of genetic testing in women with a history of breast or ovarian cancer. J Clin Oncol 35(34):3800–3806
5. Obstetricians ACo, Gynecologists, Practice CoG (2018) Cascade testing: testing women for known hereditary genetic mutations associated with cancer. ACOG committee opinion no. 727. Obstet Gynecol Surv 73(4):211–212